Compare Incyte Corporation (INCY) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Ferrari NV — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Ferrari NV trades at $406.78 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 2.9× Incyte Corporation's market cap, and Ferrari NV pays a 1.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RACE | |
|---|---|---|
Market Cap | $24.54B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $504.09 |
52-Week Low | $81.61 | $314.63 |
Enterprise Value | $20.04B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Ferrari (RACE) trades at $405.73, down 0.26% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, reaching $7.15B in 2025, with a net income margin of 22.25% and high profitability metrics like a 45.45% ROE.
The outlook remains positive given strong order books, margin expansion, and analyst consensus favoring a buy rating with a $462.67 price target. Key risks include premium valuation multiples limiting upside and sensitivity to luxury demand cycles. The stock's proximity to its 52-week high suggests momentum but warrants caution on overextension.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
